194 related articles for article (PubMed ID: 29175284)
1. Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study.
Bae JM; Kim M; Lee HH; Kim KJ; Shin H; Ju HJ; Kim GM; Park CJ; Park HJ
J Invest Dermatol; 2018 Apr; 138(4):768-774. PubMed ID: 29175284
[TBL] [Abstract][Full Text] [Related]
2. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
3. Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.
Kim MJ; Lee EE; Lee EY; Song YW; Yu HG; Choi Y; Lee EB
Clin Rheumatol; 2018 Oct; 37(10):2763-2770. PubMed ID: 30076542
[TBL] [Abstract][Full Text] [Related]
4. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis.
Lee JW; Kang JH; Yim YR; Kim JE; Wen L; Lee KE; Park DJ; Kim TJ; Park YW; Lee SS
PLoS One; 2015; 10(7):e0131864. PubMed ID: 26176701
[TBL] [Abstract][Full Text] [Related]
6. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L
Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181
[TBL] [Abstract][Full Text] [Related]
7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
8. Alopecia areata during etanercept therapy.
Pan Y; Rao NA
Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
Wolf D; Skup M; Yang H; Fang AP; Kageleiry A; Chao J; Mittal M; Lebwohl M
Clin Ther; 2017 Apr; 39(4):849-862.e6. PubMed ID: 28363696
[TBL] [Abstract][Full Text] [Related]
10. Incidence of tuberculosis among anti-tumor necrosis factor users in patients with a previous history of tuberculosis.
Jo KW; Hong Y; Jung YJ; Yoo B; Lee CK; Kim YG; Yang SK; Byeon JS; Kim KJ; Ye BD; Lee SD; Kim WS; Kim DS; Shim TS
Respir Med; 2013 Nov; 107(11):1797-802. PubMed ID: 24029000
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study.
Kim M; Choi KH; Hwang SW; Lee YB; Park HJ; Bae JM
J Am Acad Dermatol; 2017 Jan; 76(1):40-48. PubMed ID: 27793451
[TBL] [Abstract][Full Text] [Related]
12. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
[TBL] [Abstract][Full Text] [Related]
13. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
14. Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.
Jung SM; Ju JH; Park MS; Kwok SK; Park KS; Kim HY; Yim HW; Park SH
Int J Rheum Dis; 2015 Mar; 18(3):323-30. PubMed ID: 25557144
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study.
Lee JH; Kwon HS; Jung HM; Kim GM; Bae JM
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1784-1790. PubMed ID: 29761904
[TBL] [Abstract][Full Text] [Related]
16. The risk of alopecia areata and other related autoimmune diseases in patients with sleep disorders: a Korean population-based retrospective cohort study.
Seo HM; Kim TL; Kim JS
Sleep; 2018 Sep; 41(9):. PubMed ID: 29955877
[TBL] [Abstract][Full Text] [Related]
17. Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.
Psarelis S; Hajineocli APD; Hadjicosta E; Elliott HSA; Johnson P
Clin Rheumatol; 2017 May; 36(5):1197-1199. PubMed ID: 28233109
[TBL] [Abstract][Full Text] [Related]
18. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
19. High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease.
Čeović R; Desnica L; Pulanić D; Serventi Seiwerth R; Ilić I; Grce M; Mravak Stipetić M; Klepac Pulanić T; Bilić E; Bilić E; Milošević M; Vrhovac R; Nemet D; Pavletic SZ
Croat Med J; 2016 Jun; 57(3):229-38. PubMed ID: 27374824
[TBL] [Abstract][Full Text] [Related]
20. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
